Cortechs.ai Gains FDA Clearance for NeuroQuant PET
COVINGTON, Ky., August 18, 2026 Cortechs.ai announced that its NeuroQuant® PET platform has received FDA 510(k) clearance (K261916) for...
Neurodegenerative Disorders
Advertisement
Alzamend Reports Phase II AL001 Brain Data Gains
ATLANTA, United States, April 7, 2026 Alzamend Neuro, Inc. announced encouraging pharmacodynamic data from its Phase II clinical trial...
IGC Pharma Expands Phase 2 CALMA Alzheimer’s Trial
POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical...
TML-6 Advances to Global Phase 2 Alzheimer’s Trials
TAINAN, Taiwan, Feb. 9, 2026 — MerryLife Biomedical Inc. announced positive Phase 1 clinical findings for TML-6, its investigational...
Single-Molecule Proteomics Targets Alpha-Synuclein in Parkinson’s
January 28, 2026 — Nautilus Biotechnology, Weill Cornell Medicine–Qatar (WCM-Q), and The Michael J. Fox Foundation (MJFF) have launched...
Advertisements
Finger-Prick Blood Test Could Enable Early Alzheimer’s Diagnosis
London, January 19, 2026 — Scientists from a major international collaboration led by LifeArc and the Global Alzheimer’s Platform...
IRLAB Wins Approval for Phase Ib IRL757 Parkinson’s Trial
Gothenburg, Sweden | December 23, 2025 — IRLAB Therapeutics AB announced that it has received regulatory and ethical approvals...
FDA Grants Fast Track to AJ201 for Kennedy’s Disease Therapy
TAIPEI, Taiwan – October 23, 2025 AnnJi Pharmaceutical Co., Ltd. (AJ Pharm) announced that the U.S. Food and Drug...
Arrowhead Pharma and Novartis Advance RNAi Therapy for Parkinson’s
Pasadena, CA – October 21, 2025 – Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has officially completed its global licensing and...
Advertisement
